DelveInsight Business Research LLP

DelveInsight’s “Pertussis – Market Insights, Epidemiology, and Market Forecast – 2032” report delivers an in-depth understanding of the Pertussis, historical and forecasted epidemiology as well as the Pertussis market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

Key Highlights 

• Key Companies working on Pertussis   Disease include ILiAD Biotechnologies, Dynavax TechnologiesTianjin CanSino Biotechnology, Faron Pharmaceuticals, and many others 

• Key Therapies included in the Pertussis   Disease market include WAYLIVRA (volanesorsen), Olezarsen, ARO-APOC3, and many others 

Pertussis Disease Overview

Whooping cough (pertussis) is a highly contagious respiratory tract infection. In many people, it’s marked by a severe hacking cough followed by a high-pitched intake of breath that sounds like “whoop.” Before the vaccine was developed, whooping cough was considered a childhood disease.

Once infected with whooping cough, it takes about seven to 10 days for signs and symptoms to appear, though it can sometimes take longer. They’re usually mild at first and resemble those of a common cold: Runny nose, Nasal congestion, Red, watery eyes, Fever, Cough

After a week or two, signs and symptoms worsen. Thick mucus accumulates inside your airways, causing uncontrollable coughing. Severe and prolonged coughing attacks may Provoke vomiting Result in a red or blue face, Cause extreme fatigue, End with a high-pitched “whoop” sound during the next breath of air

Pertussis Disease Epidemiology Insights

• The annual worldwide incidence of pertussis is estimated to be 48.5 million cases, with a mortality rate of nearly 295,000 deaths per year.

Click here to learn more about the Pertussis Disease Market Landscape

 The Report Covers the Pertussis Disease Epidemiology Segmented by:

• Pertussis  Disease prevalent cases 

• Pertussis  Disease incident cases 

• Pertussis  Disease treatment cases 

• Pertussis  Disease diagnosed cases 

Pertussis Disease Market Outlook 

The most important way to prevent pertussis is through complete immunization. The vaccine for pertussis is usually given with diphtheria and tetanus (often in combination with poliomyelitis, H. influenza, and hepatitis B). Three vaccine formulations are available to protect against these diseases. DTaP vaccine, Tdap vaccine, and Td; before 1980, whole-cell vaccines (wPV) were used. However the wPV caused rare but significant side effects such as triggering prolonged crying and febrile convulsions and, very rarely, hypotonic–hyporesponsive episodes. After that, more defined acellular vaccines (aPVs) were developed; aPVs have improved safety profile; the efficacy of aPVs was slightly lower. Nevertheless, wPVs are still the most used vaccine globally, primarily because of the high cost of aPV, making it difficult to afford in resource-poor countries.

Treatment of pertussis is largely supportive, including oxygen, suctioning, hydration, and avoidance of respiratory irritants. Parenteral nutrition may be necessary as the disease tends to have a prolonged course. The treatment for whooping cough is usually antibiotics; the primary goal of antibiotic treatment is to decrease the carriage and spread of the disease. Erythromycin (40–50 mg/kg per day, maximum 2 g per day, in 2–3 divided doses) is the first-line treatment for pertussis. Azithromycin (10 mg/kg per day on Day 1 followed by 5 mg/kg on Days 2–5) and clarithromycin (15 mg/kg per day in two divided doses) are alternative treatments.

The Food and Drug Administration (FDA) licensed 12 combination vaccines for use in the United States to help protect against diphtheria and tetanus. Pentaxim, Infanrix, Pentacel, Vaxelis, and others are approved in the US. Although vaccination programs against pertussis are very effective in Europe, some studies show that the disease is still widespread among middle-aged adults in various European countries.

Key Companies Working in the Pertussis Disease Market

• LG Chem

• ILiAD Biotechnologies

• Dynavax Technologies

• Tianjin CanSino Biotechnology

• Faron Pharmaceuticals

• Kymab

And many others 

 Pertussis Disease Therapies Covered and Analyzed in the Report

• ADACEL

• BOOSTRIX

• BPZE1

• BK1310/MT-2355

And many others

Learn more about the Key Companies and Emerging Therapies in the Pertussis Disease Market

 Table of Contents 

1.  Key Insights 

2.  Pertussis   Disease  Introduction 

3.  Executive Summary of Pertussis Disease            

4.  Disease Background and Overview

5.  Epidemiology and patient population

6.  Pertussis   Disease  Emerging Therapies

7.  Pertussis   Disease  Market Outlook

8.  Market Access and Reimbursement of Therapies

9.  Market Drivers 

10.  Market Barriers 

11.  Appendix

12.  Report Methodology

13.  DelveInsight Capabilities

14.  Disclaimer

Learn about the detailed offerings of the report @ Pertussis Disease Market Outlook

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Adya Kaul
Email: Send Email
Phone: 919650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services